Journal of Microbiology

Reviews

REVIEW] Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease: Jin Ah Cho , Daniel J.F. Chinnapen; J. Microbiol. 2018;56(3):183-188. Published online February 28, 2018; DOI: https://doi.org/10.1007/s12275-018-8037-z

54 View
0 Download
9 Crossref

Mucosal surfaces that line our gastrointestinal tract are continuously exposed to trillions of bacteria that form a symbiotic relationship and impact host health and disease. It is only beginning to be understood that the cross-talk between the host and microbiome involve dynamic changes in commensal bacterial population, secretion, and absorption of metabolites between the host and microbiome. As emerging evidence implicates dysbiosis of gut microbiota in the pathology and progression of various diseases such as inflammatory bowel disease, obesity, and allergy, conventional treatments that either overlook the microbiome in the mechanism of action, or eliminate vast populations of microbes via wide-spectrum antibiotics need to be reconsidered. It is also becoming clear the microbiome can influence the body’s response to therapeutic treatments for cancers. As such, targeting the microbiome as treatment has garnered much recent attention and excitement from numerous research labs and biotechnology companies. Treatments range from fecal microbial transplantation to precision-guided molecular approaches. Here, we survey recent progress in the development of innovative therapeutics that target the microbiome to treat disease, and highlight key findings in the interplay between host microbes and therapy.

Citations

Citations to this article as recorded by

Manipulating the microbiome to enhance oral tolerance in food allergy
Miguel Gonzalez-Visiedo, Michael D. Kulis, David M. Markusic
Cellular Immunology.2022; 382: 104633. CrossRef
Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation
Travis T. Sims, Molly B. El Alam, Tatiana V. Karpinets, Stephanie Dorta-Estremera, Venkatesh L. Hegde, Sita Nookala, Kyoko Yoshida-Court, Xiaogang Wu, Greyson W. G. Biegert, Andrea Y. Delgado Medrano, Travis Solley, Mustapha Ahmed-Kaddar, Bhavana V. Chapm
Communications Biology.2021;[Epub] CrossRef
Natural bioactive molecules: An alternative approach to the treatment and control of glioblastoma multiforme
Priti Tagde, Pooja Tagde, Sandeep Tagde, Tanima Bhattacharya, Vishal Garg, Rokeya Akter, Md. Habibur Rahman, Agnieszka Najda, Ghadeer M. Albadrani, Amany A. Sayed, Muhammad Furqan Akhtar, Ammara Saleem, Ahmed E. Altyar, Deepak Kaushik, Mohamed M. Abdel-Da
Biomedicine & Pharmacotherapy.2021; 141: 111928. CrossRef
Gut microbiota restoration through fecal microbiota transplantation: a new atopic dermatitis therapy
Jong-Hwa Kim, Kiyoung Kim, Wonyong Kim
Experimental & Molecular Medicine.2021; 53(5): 907. CrossRef
Effects of Antibiotic Pretreatment of an Ulcerative Colitis-Derived Fecal Microbial Community on the Integration of Therapeutic Bacteria In Vitro
Kaitlyn Oliphant, Kyla Cochrane, Kathleen Schroeter, Michelle C. Daigneault, Sandi Yen, Elena F. Verdu, Emma Allen-Vercoe, Pieter C. Dorrestein
mSystems.2020;[Epub] CrossRef
The Role of the Microbiome in Food Allergy: A Review
Christina L. Nance, Roman Deniskin, Veronica C. Diaz, Misu Paul, Sara Anvari, Aikaterini Anagnostou
Children.2020; 7(6): 50. CrossRef
Computational Prediction of a New ADMET Endpoint for Small Molecules: Anticommensal Effect on Human Gut Microbiota
Suqing Zheng, Wenping Chang, Wenxin Liu, Guang Liang, Yong Xu, Fu Lin
Journal of Chemical Information and Modeling.2019; 59(3): 1215. CrossRef
Contribution of Non-immune Cells to Activation and Modulation of the Intestinal Inflammation
Renata Curciarello, Karina Eva Canziani, Guillermo Horacio Docena, Cecilia Isabel Muglia
Frontiers in Immunology.2019;[Epub] CrossRef
Gut microbiomes and their metabolites shape human and animal health
Woojun Park
Journal of Microbiology.2018; 56(3): 151. CrossRef

MINIREVIEW] The Role of MicroRNAs in Hepatitis C Virus Replication and Related Liver Diseases: Chang Ho Lee , Ji Hyun Kim , Seong-Wook Lee; J. Microbiol. 2014;52(6):445-451. Published online May 29, 2014; DOI: https://doi.org/10.1007/s12275-014-4267-x

53 View
0 Download
32 Crossref

Abstract

Hepatitis C virus (HCV) infection is a worldwide health problem and is one of the main causes of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). However, only limited therapeutic options and no vaccines are currently available against HCV infection. Recent studies of microRNAs (miRNAs), which are able to regulate HCV replication and its related liver diseases by directly interacting with the HCV genome or indirectly controlling virus-associated host pathways, have broadened our understanding of the HCV life cycle. HCV utilizes host cellular miRNAs and modulates expression of miRNAs in infected hepatocytes for its infection and propagation. Moreover, such miRNAs directly or indirectly alter HCV replication efficiency and induce liver diseases including liver fibrosis, cirrhosis, or HCC. Representatively, miR-122 directly modulates the HCV life cycle by increasing HCV translation and genomic RNA stability. Recently, a phase IIa clinical trial with miravirsen, an LNA form of antimiR-122 oligonucleotides, showed significant reduction in serum HCV levels in patients chronically infected with HCV with no detectible evidence of resistance. In addition to miR-122, other miRNAs involved in the regulation of HCV propagation could be targeted in strategies to modulate HCV replication and pathogenesis. In this review, we summarize the features of miRNAs critical for HCV replication and HCV-mediated liver abnormalities and briefly discuss their potential application as therapeutic reagents for the treatment of HCV infection and its related diseases.

Citations

Citations to this article as recorded by

MiR-130c-5p targets the SHVV n gene and upregulates immune cytokines (IL-6, IL-22, IL-1β) to inhibit viral replication
Jin Wei, Yan Ji, Yaqian Bai, Rui Cheng, Jiaqi Zhang, Xianqin Hu, Chi Zhang
Frontiers in Immunology.2024;[Epub] CrossRef
Research advances in serum chitinase-3-like protein 1 in liver fibrosis
Xingwei Hu, Wenhan Liu, Jianhua Liu, Bojian Wang, Xiaosong Qin
Frontiers in Medicine.2024;[Epub] CrossRef
A Review of miRNA Regulation in Japanese Encephalitis (JEV) Virus Infection
Maneesh Kumar, Ganesh Chandra Sahoo, Vidya Nand Rabi Das, Kamal Singh, Krishna Pandey
Current Pharmaceutical Biotechnology.2024; 25(5): 521. CrossRef
Cold exposure impairs extracellular vesicle swarm–mediated nasal antiviral immunity
Di Huang, Maie S. Taha, Angela L. Nocera, Alan D. Workman, Mansoor M. Amiji, Benjamin S. Bleier
Journal of Allergy and Clinical Immunology.2023; 151(2): 509. CrossRef
Circulating miRNA-192 and miR-29a as Disease Progression Biomarkers in Hepatitis C Patients with a Prevalence of HCV Genotype 3
Amin Ullah, Irshad Ur Rehman, Katharina Ommer, Nadeem Ahmed, Margarete Odenthal, Xiaojie Yu, Jamshaid Ahmad, Tariq Nadeem, Qurban Ali, Bashir Ahmad
Genes.2023; 14(5): 1056. CrossRef
Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches
Ester Badami, Rosalia Busà, Bruno Douradinha, Giovanna Russelli, Vitale Miceli, Alessia Gallo, Giovanni Zito, Pier Giulio Conaldi, Gioacchin Iannolo
World Journal of Gastroenterology.2022; 28(22): 2417. CrossRef
Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma
Mirjam B. Zeisel, Francesca Guerrieri, Massimo Levrero
Journal of Clinical Medicine.2021; 10(8): 1715. CrossRef
MiRNAs and Cancer: Key Link in Diagnosis and Therapy
Yu Shi, Zihao Liu, Qun Lin, Qing Luo, Yinghuan Cen, Juanmei Li, Xiaolin Fang, Chang Gong
Genes.2021; 12(8): 1289. CrossRef
Circulating microRNA-155 is associated with insulin resistance in chronic hepatitis C patients
Nourhan M. El Samaloty, Zeinab A. Hassan, Zeinab M. Hefny, Dalia H.A. Abdelaziz
Arab Journal of Gastroenterology.2019; 20(1): 1. CrossRef
Integrated Analysis of miRNA and mRNA Expression Profiles in Spleen of Specific Pathogen-Free Chicken Infected with Avian Reticuloendotheliosis Virus Strain SNV
Shuo Gao, Hao Jiang, Jie Sun, Youxiang Diao, Yi Tang, Jingdong Hu
International Journal of Molecular Sciences.2019; 20(5): 1041. CrossRef
Molecular mechanisms of circular RNAs, transforming growth factor‐β, and long noncoding RNAs in hepatocellular carcinoma
Wenkang Shang, Gabriel Komla Adzika, Yujie Li, Qike Huang, Ningding Ding, Bianca Chinembiri, Mohammad Sajjad Ibn Rashid, Jeremiah Ong'achwa Machuki
Cancer Medicine.2019; 8(15): 6684. CrossRef
MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma
Gábor Lendvai, Tímea Szekerczés, Benedek Gyöngyösi, Krisztina Schlachter, Endre Kontsek, Adrián Pesti, Attila Patonai, Klára Werling, Ilona Kovalszky, Zsuzsa Schaff, András Kiss
Pathology & Oncology Research.2019; 25(3): 1103. CrossRef
gga-miR-21 modulates Mycoplasma gallisepticum (HS strain)-Induced inflammation via targeting MAP3K1 and activating MAPKs and NF-κB pathways
Yabo Zhao, Mengyun Zou, Yingfei Sun, Kang Zhang, Xiuli Peng
Veterinary Microbiology.2019; 237: 108407. CrossRef
miR-27b-mediated suppression of aquaporin-11 expression in hepatocytes reduces HCV genomic RNA levels but not viral titers
Fuminori Sakurai, Rina Hashimoto, Chieko Inoue, Keisaku Wakabayashi, Tomohito Tsukamoto, Tsutomu Imaizumi, Taracena Gandara Marcos Andres, Eiko Sakai, Kanae Itsuki, Naoya Sakamoto, Takaji Wakita, Hiroyuki Mizuguchi
Virology Journal.2019;[Epub] CrossRef
Novel Insights on Notch signaling pathways in liver fibrosis
Ming-ming Ni, Ya-rui Wang, Wen-wen Wu, Chong-cai Xia, Yi-he Zhang, Jing Xu, Tao Xu, Jun Li
European Journal of Pharmacology.2018; 826: 66. CrossRef
Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma
Marie-Laure Plissonnier, Katharina Herzog, Massimo Levrero, Mirjam B. Zeisel
Viruses.2018; 10(11): 591. CrossRef
Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma
Man Wang, Fei Yu, Peifeng Li
Cancers.2018; 10(8): 258. CrossRef
Upregulated microRNA-429 inhibits the migration of HCC cells by targeting TRAF6 through the NF-κB pathway
Peng Wang, Jia Cao, Shihai Liu, Huazheng Pan, Xiangping Liu, Aihua Sui, Liping Wang, Ruyong Yao, Zimin Liu, Jun Liang
Oncology Reports.2017; 37(5): 2883. CrossRef
Hepatitis C virus and atherosclerosis: A legacy after virologic cure?
M.F. Bassendine, S.U. Nielsen, S.H. Bridge, D.J. Felmlee, D.A. Sheridan, C.J. Packard, R.D. Neely
Clinics and Research in Hepatology and Gastroenterology.2017; 41(1): 25. CrossRef
The Potential of MicroRNAs as Novel Biomarkers for Transplant Rejection
Matthias Hamdorf, Satoru Kawakita, Matthew Everly
Journal of Immunology Research.2017; 2017: 1. CrossRef
The notorious R.N.A. in the spotlight - drug or target for the treatment of disease
Philipp Reautschnig, Paul Vogel, Thorsten Stafforst
RNA Biology.2017; 14(5): 651. CrossRef
Decline of miR‐124 in myeloid cells promotes regulatory T‐cell development in hepatitis C virus infection
Jun P. Ren, Lin Wang, Juan Zhao, Ling Wang, Shun B. Ning, Mohamed El Gazzar, Jonathan P. Moorman, Zhi Q. Yao
Immunology.2017; 150(2): 213. CrossRef
Protection of CD4+ T cells from hepatitis C virus infection-associated senescence via ΔNp63–miR-181a–Sirt1 pathway
Yun Zhou, Guang Y Li, Jun P Ren, Ling Wang, Juan Zhao, Shun B Ning, Ying Zhang, Jian Q Lian, Chang X Huang, Zhan S Jia, Jonathan P Moorman, Zhi Q Yao
Journal of Leukocyte Biology.2016; 100(5): 1201. CrossRef
Achieving sustained virologic response after interferon‐free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis
E. G. Meissner, A. Kohli, K. Virtaneva, D. Sturdevant, C. Martens, S. F. Porcella, J. G. McHutchison, H. Masur, S. Kottilil
Journal of Viral Hepatitis.2016; 23(7): 496. CrossRef
MicroRNA-mediated interactions between host and hepatitis C virus
Hu Li
World Journal of Gastroenterology.2016; 22(4): 1487. CrossRef
Hepatitis C virus infection stimulates transforming growth factor-β1 expression through up-regulating miR-192
Ji Hyun Kim, Chang Ho Lee, Seong-Wook Lee
Journal of Microbiology.2016; 54(7): 520. CrossRef
MicroRNA-33a-5p Modulates Japanese Encephalitis Virus Replication by Targeting Eukaryotic Translation Elongation Factor 1A1
Zheng Chen, Jing Ye, Usama Ashraf, Yunchuan Li, Siqi Wei, Shengfeng Wan, Ali Zohaib, Yunfeng Song, Huanchun Chen, Shengbo Cao, R. M. Sandri-Goldin
Journal of Virology.2016; 90(7): 3722. CrossRef
Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection
Christian Jansen, Thomas Reiberger, Jia Huang, Hannah Eischeid, Robert Schierwagen, Mattias Mandorfer, Evrim Anadol, Philipp Schwabl, Carolynne Schwarze-Zander, Ute Warnecke-Eberz, Christian P. Strassburg, Jürgen K. Rockstroh, Markus Peck-Radosavljevic, M
PLOS ONE.2015; 10(2): e0116768. CrossRef
Advances, Nuances, and Potential Pitfalls When Exploiting the Therapeutic Potential of RNA Interference
M Battistella, PA Marsden
Clinical Pharmacology & Therapeutics.2015; 97(1): 79. CrossRef
Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases
Jason Lamontagne
World Journal of Gastroenterology.2015; 21(24): 7375. CrossRef
Hepatitis C virus–induced reduction in miR‐181a impairs CD4+ T‐cell responses through overexpression of DUSP6
Guang Y. Li, Yun Zhou, Ruo S. Ying, Lei Shi, Yong Q. Cheng, Jun P. Ren, Jeddidiah W.D. Griffin, Zhan S. Jia, Chuan F. Li, Jonathan P. Moorman, Zhi Q. Yao
Hepatology.2015; 61(4): 1163. CrossRef
miR-141 targets ZEB2 to suppress HCC progression
Shi-Min Wu, Hong-Wu Ai, Ding-Yu Zhang, Xiao-Qun Han, Qin Pan, Feng-Ling Luo, Xiao-Lian Zhang
Tumor Biology.2014; 35(10): 9993. CrossRef

MINIREVIEW] Nontraditional Therapies to Treat Helicobacter pylori Infection: Morris O. Makobongo , Jeremy J. Gilbreath , D. Scott Merrell; J. Microbiol. 2014;52(4):259-272. Published online March 29, 2014; DOI: https://doi.org/10.1007/s12275-014-3603-5

56 View
0 Download
20 Crossref

Abstract

The Gram-negative pathogen Helicobacter pylori is increasingly more resistant to the three major antibiotics (metronidazole, clarithromycin and amoxicillin) that are most commonly used to treat infection. As a result, there is an increased rate of treatment failure; this translates into an overall higher cost of treatment due to the need for increased length of treatment and/or the requirement for combination or sequential therapy. Given the rise in antibiotic resistance, the complicated treatment regime, and issues related to patient compliance that stem from the duration and complexity of treatment, there is clearly a pressing need for the development of novel therapeutic strategies to combat H. pylori infection. As such, researchers are actively investigating the utility of antimicrobial peptides, small molecule inhibitors and naturopathic therapies. Herein we review and discuss each of these novel approaches as a means to target this important gastric pathogen.

Citations

Citations to this article as recorded by

Pistacia vera L. as natural source against antimicrobial and antiviral resistance
Giuseppina Mandalari, Rosamaria Pennisi, Teresa Gervasi, Maria Teresa Sciortino
Frontiers in Microbiology.2024;[Epub] CrossRef
Efficacy of a standardised herbal formulation in Helicobacter pylori positive patients with gastritis or peptic ulcer: a triple-blind randomised clinical trial
Arefe Shojaeian, Alireza Khalilian, Maryam Mehrpoya, Jalal Poorolajal, Dara Dastan
Journal of Herbal Medicine.2023; 41: 100706. CrossRef
Antibacterial, Antibiofilm, and Antioxidant Activity of 15 Different Plant-Based Natural Compounds in Comparison with Ciprofloxacin and Gentamicin
Ali Pormohammad, Dave Hansen, Raymond J. Turner
Antibiotics.2022; 11(8): 1099. CrossRef
Targeting the Essential Transcription Factor HP1043 of Helicobacter pylori: A Drug Repositioning Study
Federico Antoniciello, Davide Roncarati, Annamaria Zannoni, Elena Chiti, Vincenzo Scarlato, Federica Chiappori
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
Helicobacter pylori eradication: Exploring its impacts on the gastric mucosa
Chun-Yan Weng, Jing-Li Xu, Shao-Peng Sun, Kai-Jie Wang, Bin Lv
World Journal of Gastroenterology.2021; 27(31): 5152. CrossRef
A Comprehensive Study on the Antimicrobial Properties of Resveratrol as an Alternative Therapy
Ehsan Abedini, Ehsaneh Khodadadi, Elham Zeinalzadeh, Seyyed Reza Moaddab, Mohammad Asgharzadeh, Bahareh Mehramouz, Sounkalo Dao, Hossein Samadi Kafil, Weicheng Hu
Evidence-Based Complementary and Alternative Medicine.2021; 2021: 1. CrossRef
Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice
Patrícia C. Henriques, Lia M. Costa, Catarina L. Seabra, Bernardo Antunes, Ricardo Silva-Carvalho, Susana Junqueira-Neto, André F. Maia, Pedro Oliveira, Ana Magalhães, Celso A. Reis, Fátima Gartner, Eliette Touati, Joana Gomes, Paulo Costa, M. Cristina L.
Acta Biomaterialia.2020; 114: 206. CrossRef
Effects of cinnamon extract on complications of treatment and eradication of Helicobacter pylori in infected people
Ghazal Imani, Alireza khalilian, Dara Dastan, Behzad Imani, Maryam Mehrpoya
Journal of Herbmed Pharmacology.2020; 9(1): 55. CrossRef
Flacourtia indica based biogenic nanoparticles: development, characterization, and bioactivity against wound associated pathogens
Farooq Ahmad, Muhammad Babar Taj, Muhammad Ramzan, Ahmad Raheel, Saima Shabbir, Muhammad Imran, Hafiz M N Iqbal
Materials Research Express.2020; 7(1): 015026. CrossRef
In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori
Faith C. Blum, Jatinder Singh, D. Scott Merrell
Journal of Ethnopharmacology.2019; 232: 236. CrossRef
Study of inhibitory effects of the mixture of cinnamon and ginger extracts on cagA gene expression of Helicobacter pylori by Real-Time RT-PCR technique
Morteza Azadi, Asa Ebrahimi, Azad Khaledi, Davoud Esmaeili
Gene Reports.2019; 17: 100493. CrossRef
In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains
Jun-Won Chung, Su Young Kim, Hee Jung Park, Chang Su Chung, Hee Woo Lee, Sun Mi Lee, Inki Kim, Jhang Ho Pak, Gin Hyug Lee, Jin-Yong Jeong
Gut and Liver.2017; 11(5): 648. CrossRef
Helicobacter pylori treatment: New perspectives using current experience
Amin Talebi Bezmin Abadi
Journal of Global Antimicrobial Resistance.2017; 8: 123. CrossRef
Selective killing of Helicobacter pylori with pH-responsive helix–coil conformation transitionable antimicrobial polypeptides
Menghua Xiong, Yan Bao, Xin Xu, Hua Wang, Zhiyuan Han, Zhiyu Wang, Yeqing Liu, Songyin Huang, Ziyuan Song, Jinjing Chen, Richard M. Peek, Lichen Yin, Lin-Feng Chen, Jianjun Cheng
Proceedings of the National Academy of Sciences.2017; 114(48): 12675. CrossRef
Helicobacter pylori outer membrane protein, HomC, shows geographic dependent polymorphism that is influenced by the Bab family
Aeryun Kim, Stephanie L. Servetas, Jieun Kang, Jinmoon Kim, Sungil Jang, Yun Hui Choi, Hanfu Su, Yeong-Eui Jeon, Youngmin A. Hong, Yun-Jung Yoo, D. Scott Merrell, Jeong-Heon Cha
Journal of Microbiology.2016; 54(12): 846. CrossRef
Capsule Design for Blue Light Therapy against Helicobacter pylori
Zhangyong Li, Binbin Ren, Haiyan Tan, Shengrong Liu, Wei Wang, Yu Pang, Jinzhao Lin, Chen Zeng, Dipshikha Chakravortty
PLOS ONE.2016; 11(1): e0147531. CrossRef
Morphological changes in human gastric epithelial cells induced by nuclear targeting of Helicobacter pylori urease subunit A
Jung Hwa Lee, So Hyun Jun, Jung-Min Kim, Seung Chul Baik, Je Chul Lee
Journal of Microbiology.2015; 53(6): 406. CrossRef
Dietary amelioration of Helicobacter infection
Jed W. Fahey, Katherine K. Stephenson, Alison J. Wallace
Nutrition Research.2015; 35(6): 461. CrossRef
Antibiotic treatment forHelicobacter pylori: Is the end coming?
Su Young Kim
World Journal of Gastrointestinal Pharmacology and Therapeutics.2015; 6(4): 183. CrossRef
The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection
Inês C Gonçalves, Patrícia C Henriques, Catarina L Seabra, M Cristina L Martins
Expert Review of Anti-infective Therapy.2014; 12(8): 981. CrossRef

First
Prev
Page of 1
Next
Last

Search